Abstract
Objective: To identify subsets of chronic obstructive pulmonary disease (COPD) patients who are more protected from exacerbations with the use of an inhaled corticosteroid/long-acting β 2 agonist (ICS/LABA) combination, compared with the use of LABA monotherapy. Design: Post hoc cluster analysis of patients from two randomised clinical trials of salmeterol/fluticasone propionate (SFC) and salmeterol (SAL) that had primary endpoints of moderate/severe exacerbation rates. Setting: Centres in North America. Participants: 1543 COPD patients were studied. Interventions: SFC 50/250 µg or SAL 50 µg, twice daily. Primary and secondary outcome measures: The analysis identified clusters of COPD patients more responsive to SFC versus SAL with respect to the annual rate of moderate/severe exacerbations and compared their baseline clinical characteristics. Results: Overall, SFC significantly reduced the annual rate of moderate/severe exacerbations as compared with SAL alone (rate ratio (RR)=0.701, p1 ) reversibility ≥12% (RR=0.67, p12% at baseline were significantly more likely to experience a reduction in COPD-associated exacerbations with SFC versus SAL alone. Trial registration: NCT00115492, NCT00144911

This publication has 48 references indexed in Scilit: